These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 3033253)

  • 1. Survival of patients with unresectable non-small cell lung cancer following 6,000 rad megavoltage radiotherapy.
    Kumar PP; Good RR; Hynes PR; Plantz SH; Somers JE; McAnulty BE; McCaul GF; Rogers SS; Reeves MA
    J Natl Med Assoc; 1987 Mar; 79(3):313-21. PubMed ID: 3033253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
    Liao Z; Komaki R; Milas L; Yuan C; Kies M; Chang JY; Jeter M; Guerrero T; Blumenschien G; Smith CM; Fossella F; Brown B; Cox JD
    Clin Cancer Res; 2005 May; 11(9):3342-8. PubMed ID: 15867233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformal high dose external radiation therapy, 80.5 Gy, alone for medically inoperable non-small cell lung cancer: a retrospective analysis.
    Urbanic JJ; Turrisi AT; Sharma AK; Silvestri GA; Williams TE; Vanek KN; Sherman CA
    J Thorac Oncol; 2006 Feb; 1(2):112-9. PubMed ID: 17409839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daily low-dose cisplatin plus concurrent high-dose thoracic irradiation in locally advanced unresectable non-small-cell lung cancer: results of a phase II Southwest Oncology Group study.
    Hazuka MB; Crowley JJ; Bunn PA; O'Rourke M; Braun TJ; Livingston RB
    J Clin Oncol; 1994 Sep; 12(9):1814-20. PubMed ID: 8083705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II study of treatment of locally advanced (T3/T4) non-oat cell lung cancer with concomitant boost radiotherapy by the Radiation Therapy Oncology Group (RTOG 83-12): long-term results.
    Graham MV; Pajak TE; Herskovic AM; Emami B; Perez CA
    Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):819-25. PubMed ID: 7860394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial.
    Sundstrøm S; Bremnes R; Aasebø U; Aamdal S; Hatlevoll R; Brunsvig P; Johannessen DC; Klepp O; Fayers PM; Kaasa S
    J Clin Oncol; 2004 Mar; 22(5):801-10. PubMed ID: 14990635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Escalated hyperfractionated accelerated radiation therapy for locally advanced non-small cell lung cancer: a clinical phase II trial.
    Chen GY; Jiang GL; Qian H; Wang LJ; Yang HJ; Fu XL; Wu KL; Zang Z; Zhao S
    Radiother Oncol; 2004 May; 71(2):157-62. PubMed ID: 15110448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial megavoltage CT imaging during external beam radiotherapy for non-small-cell lung cancer: observations on tumor regression during treatment.
    Kupelian PA; Ramsey C; Meeks SL; Willoughby TR; Forbes A; Wagner TH; Langen KM
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1024-8. PubMed ID: 16005575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypofractionated Image-guided Radiation Therapy (3Gy/fraction) in Patients Affected by Inoperable Advanced-stage Non-small Cell Lung Cancer After Long-term Follow-up.
    Agolli L; Valeriani M; Bracci S; Nicosia L; DE Sanctis V; Enrici RM; Osti MF
    Anticancer Res; 2015 Oct; 35(10):5693-700. PubMed ID: 26408745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer.
    Rosenzweig KE; Mychalczak B; Fuks Z; Hanley J; Burman C; Ling CC; Armstrong J; Ginsberg R; Kris MG; Raben A; Leibel S
    Cancer J; 2000; 6(2):82-7. PubMed ID: 11069224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol.
    Blanke C; Ansari R; Mantravadi R; Gonin R; Tokars R; Fisher W; Pennington K; O'Connor T; Rynard S; Miller M
    J Clin Oncol; 1995 Jun; 13(6):1425-9. PubMed ID: 7751888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study.
    Kong FM; Ten Haken RK; Schipper MJ; Sullivan MA; Chen M; Lopez C; Kalemkerian GP; Hayman JA
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):324-33. PubMed ID: 16168827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inoperable non-small cell lung cancer: palliative radiotherapy with two weekly fractions.
    Vyas RK; Suryanarayana U; Dixit S; Singhal S; Bhavsar DC; Neema JP; Baboo HA
    Indian J Chest Dis Allied Sci; 1998; 40(3):171-4. PubMed ID: 9919836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial.
    Krzakowski M; Provencio M; Utracka-Hutka B; Villa E; Codes M; Kuten A; Henke M; Lopez M; Bell D; Biti G; Merimsky O; Beorchia A; Riggi M; Caux NR; Pouget JC; Dubray B; David P
    J Thorac Oncol; 2008 Sep; 3(9):994-1002. PubMed ID: 18758302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of concurrent radiotherapy and chemotherapy for unresectable stage III non-small-cell lung cancer. Southern Osaka Lung Cancer Study Group.
    Furuse K; Kubota K; Kawahara M; Kodama N; Ogawara M; Akira M; Nakajima S; Takada M; Kusunoki Y; Negoro S
    J Clin Oncol; 1995 Apr; 13(4):869-75. PubMed ID: 7707113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
    Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
    Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy.
    Onimaru R; Fujino M; Yamazaki K; Onodera Y; Taguchi H; Katoh N; Hommura F; Oizumi S; Nishimura M; Shirato H
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):374-81. PubMed ID: 18029106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients.
    Gielda BT; Marsh JC; Zusag TW; Faber LP; Liptay M; Basu S; Warren WH; Fidler MJ; Batus M; Abrams RA; Bonomi P
    J Thorac Oncol; 2011 Jun; 6(6):1079-86. PubMed ID: 21532501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group.
    Clamon G; Herndon J; Cooper R; Chang AY; Rosenman J; Green MR
    J Clin Oncol; 1999 Jan; 17(1):4-11. PubMed ID: 10458211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity and outcome results of a class solution with moderately hypofractionated radiotherapy in inoperable Stage III non-small cell lung cancer using helical tomotherapy.
    Bral S; Duchateau M; Versmessen H; Engels B; Tournel K; Vinh-Hung V; De Ridder M; Schallier D; Storme G
    Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1352-9. PubMed ID: 20056350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.